Format

Send to

Choose Destination
See comment in PubMed Commons below
Front Genet. 2012 Jul 2;3:120. doi: 10.3389/fgene.2012.00120. eCollection 2012.

miR-34 - a microRNA replacement therapy is headed to the clinic.

Author information

1
Mirna Therapeutics, Inc.,Austin, TX, USA.

Abstract

MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. This broad anti-oncogenic activity holds the prospect of creating a new remedy that is effective against tumor heterogeneity. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic.

KEYWORDS:

miR-34; miR-34a; miRNA; miRNA replacement; miRNA therapeutics

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Frontiers Media SA Icon for PubMed Central
    Loading ...
    Support Center